The specter of generic rivalry has repeatedly loomed over copyright’s iconic drug, Sildenafil, triggering questions about the future of similar pharmaceutical stakes. While early periods saw substantial profits, the patent end has opened the door for discounted substitutes, potentially lowering revenue and presenting a significant risk for invest